FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2972310482> ?p ?o ?g. }

• W2972310482 endingPage "3504" @default.
• W2972310482 startingPage "3497" @default.
• W2972310482 abstract "Abstract Objectives To investigate the in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against clinical isolates of MDR Pseudomonas aeruginosa from Qatar, as well as the mechanisms of resistance. Methods MDR P. aeruginosa isolated between October 2014 and September 2015 from all public hospitals in Qatar were included. The BD PhoenixTM system was used for identification and initial antimicrobial susceptibility testing, while Liofilchem MIC Test Strips (Liofilchem, Roseto degli Abruzzi, Italy) were used for confirmation of ceftazidime/avibactam and ceftolozane/tazobactam susceptibility. Ten ceftazidime/avibactam- and/or ceftolozane/tazobactam-resistant isolates were randomly selected for WGS. Results A total of 205 MDR P. aeruginosa isolates were included. Of these, 141 (68.8%) were susceptible to ceftazidime/avibactam, 129 (62.9%) were susceptible to ceftolozane/tazobactam, 121 (59.0%) were susceptible to both and 56 (27.3%) were susceptible to neither. Twenty (9.8%) isolates were susceptible to ceftazidime/avibactam but not to ceftolozane/tazobactam and only 8 (3.9%) were susceptible to ceftolozane/tazobactam but not to ceftazidime/avibactam. Less than 50% of XDR isolates were susceptible to ceftazidime/avibactam or ceftolozane/tazobactam. The 10 sequenced isolates belonged to six different STs and all produced AmpC and OXA enzymes; 5 (50%) produced ESBL and 4 (40%) produced VIM enzymes. Conclusions MDR P. aeruginosa susceptibility rates to ceftazidime/avibactam and ceftolozane/tazobactam were higher than those to all existing antipseudomonal agents, except colistin, but were less than 50% in extremely resistant isolates. Non-susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam was largely due to the production of ESBL and VIM enzymes. Ceftazidime/avibactam and ceftolozane/tazobactam are possible options for some patients with MDR P. aeruginosa in Qatar." @default.
• W2972310482 created "2019-09-19" @default.
• W2972310482 creator A5000611736 @default.
• W2972310482 creator A5032336593 @default.
• W2972310482 creator A5037758591 @default.
• W2972310482 creator A5043659669 @default.
• W2972310482 creator A5050859627 @default.
• W2972310482 creator A5055043355 @default.
• W2972310482 creator A5058358658 @default.
• W2972310482 creator A5059133100 @default.
• W2972310482 creator A5061621036 @default.
• W2972310482 creator A5065683533 @default.
• W2972310482 creator A5072451871 @default.
• W2972310482 creator A5074152003 @default.
• W2972310482 creator A5077530125 @default.
• W2972310482 creator A5086083402 @default.
• W2972310482 date "2019-09-03" @default.
• W2972310482 modified "2023-10-18" @default.
• W2972310482 title "Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar" @default.
• W2972310482 cites W1494430785 @default.
• W2972310482 cites W1572900409 @default.
• W2972310482 cites W1959513603 @default.
• W2972310482 cites W1969201253 @default.
• W2972310482 cites W1971489011 @default.
• W2972310482 cites W2004548026 @default.
• W2972310482 cites W2007638964 @default.
• W2972310482 cites W2027225993 @default.
• W2972310482 cites W2054246318 @default.
• W2972310482 cites W2071605567 @default.
• W2972310482 cites W2075287054 @default.
• W2972310482 cites W2087865186 @default.
• W2972310482 cites W2091219913 @default.
• W2972310482 cites W2092279762 @default.
• W2972310482 cites W2098310975 @default.
• W2972310482 cites W2102821548 @default.
• W2972310482 cites W2103121782 @default.
• W2972310482 cites W2103382313 @default.
• W2972310482 cites W2117043113 @default.
• W2972310482 cites W2119209016 @default.
• W2972310482 cites W2120902911 @default.
• W2972310482 cites W2131610691 @default.
• W2972310482 cites W2141105958 @default.
• W2972310482 cites W2142343447 @default.
• W2972310482 cites W2142678478 @default.
• W2972310482 cites W2152944378 @default.
• W2972310482 cites W2160163108 @default.
• W2972310482 cites W2163198910 @default.
• W2972310482 cites W2168484428 @default.
• W2972310482 cites W2171155970 @default.
• W2972310482 cites W2260847212 @default.
• W2972310482 cites W2292670835 @default.
• W2972310482 cites W2301543346 @default.
• W2972310482 cites W2321935392 @default.
• W2972310482 cites W2345096571 @default.
• W2972310482 cites W2530812453 @default.
• W2972310482 cites W2544493586 @default.
• W2972310482 cites W2561647996 @default.
• W2972310482 cites W2591044857 @default.
• W2972310482 cites W2623315557 @default.
• W2972310482 cites W2724943347 @default.
• W2972310482 cites W2732025234 @default.
• W2972310482 cites W2739079221 @default.
• W2972310482 cites W2756597151 @default.
• W2972310482 cites W2763408425 @default.
• W2972310482 cites W2769664028 @default.
• W2972310482 cites W2772039013 @default.
• W2972310482 cites W2802825811 @default.
• W2972310482 cites W2804230504 @default.
• W2972310482 cites W2902567904 @default.
• W2972310482 cites W2941231904 @default.
• W2972310482 cites W2944722759 @default.
• W2972310482 cites W4230357700 @default.
• W2972310482 cites W4256343182 @default.
• W2972310482 doi "https://doi.org/10.1093/jac/dkz379" @default.
• W2972310482 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6857196" @default.
• W2972310482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31504587" @default.
• W2972310482 hasPublicationYear "2019" @default.
• W2972310482 type Work @default.
• W2972310482 sameAs 2972310482 @default.
• W2972310482 citedByCount "23" @default.
• W2972310482 countsByYear W29723104822020 @default.
• W2972310482 countsByYear W29723104822021 @default.
• W2972310482 countsByYear W29723104822022 @default.
• W2972310482 countsByYear W29723104822023 @default.
• W2972310482 crossrefType "journal-article" @default.
• W2972310482 hasAuthorship W2972310482A5000611736 @default.
• W2972310482 hasAuthorship W2972310482A5032336593 @default.
• W2972310482 hasAuthorship W2972310482A5037758591 @default.
• W2972310482 hasAuthorship W2972310482A5043659669 @default.
• W2972310482 hasAuthorship W2972310482A5050859627 @default.
• W2972310482 hasAuthorship W2972310482A5055043355 @default.
• W2972310482 hasAuthorship W2972310482A5058358658 @default.
• W2972310482 hasAuthorship W2972310482A5059133100 @default.
• W2972310482 hasAuthorship W2972310482A5061621036 @default.
• W2972310482 hasAuthorship W2972310482A5065683533 @default.
• W2972310482 hasAuthorship W2972310482A5072451871 @default.
• W2972310482 hasAuthorship W2972310482A5074152003 @default.
• W2972310482 hasAuthorship W2972310482A5077530125 @default.

• next